Androgen receptor (AR) target genes direct development and survival of the prostate epithelial lineage, including prostate cancer (PCa). Thus, endocrine therapies that inhibit the AR ligand-binding domain (LBD) are effective in treating PCa. AR transcriptional reactivation is central to resistance, as evidenced by the efficacy of AR retargeting in castration-resistant PCa (CRPC) with next-generation endocrine therapies abiraterone and enzalutamide. However, resistance to abiraterone and enzalutamide limits this efficacy in most men, and PCa remains the second-leading cause of male cancer deaths. Here we show that AR gene rearrangements in CRPC tissues underlie a completely androgen-independent, yet AR-dependent, resistance mechanism. We discovered intragenic AR gene rearrangements in CRPC tissues, which we modeled using transcription activator-like effector nuclease (TALEN)-mediated genome engineering. This modeling revealed that these AR gene rearrangements blocked full-length AR synthesis, but promoted expression of truncated AR variant proteins lacking the AR ligand-binding domain. Furthermore, these AR variant proteins maintained the constitutive activity of the AR transcriptional program and a CRPC growth phenotype independent of full-length AR or androgens. These findings demonstrate that AR gene rearrangements are a unique resistance mechanism by which AR transcriptional activity can be uncoupled from endocrine regulation in CRPC. P rostate cancer (PCa) is the most commonly diagnosed cancer in men and is the second-leading cause of male cancer mortality (1) . The androgen receptor (AR) is a steroid receptor transcription factor that drives prostate development and homeostasis and is crucial for PCa growth and survival (2) . The AR gene is located on the X chromosome and encodes a modular protein consisting of three major domains. Exon 1 encodes the NH 2 -terminal domain (NTD), exons 2 and 3 encode a central DNA-binding domain (DBD), and exons 4-8 encode the COOH-terminal ligand-binding domain (LBD). The NTD is responsible for the majority of AR transcriptional activity, but this activity is suppressed by the LBD unless AR is bound to testosterone or dihydrotestosterone (DHT) (3) (4) (5) (6) (7) . Currently, advanced or metastatic PCa is treated by systemic inhibition of androgen synthesis and antiandrogens that bind to the AR LBD (8) ; however, despite robust responses to these endocrine therapies, castration-resistant PCa (CRPC) inevitably develops concurrent with AR transcriptional reactivation (9, 10) .
Identification of AR overexpression and high tissue androgen levels as mechanisms driving AR reactivation in a subset of CRPC tumors led to the clinical development and recent approval of abiraterone and enzalutamide as new endocrine targeting therapies for treatment of CRPC (11) (12) (13) (14) (15) (16) (17) . However, despite the success of these drugs at improving overall survival, primary and secondary resistance remains a major limitation for most patients. Point mutations in the AR LBD have been implicated in resistance to enzalutamide in CRPC cell line models (18) . Similarly, increased intratumoral steroidogenesis has been observed in CRPC xenograft models that have developed resistance to abiraterone (19) . These findings support continued efforts to block the ligand-LBD interaction to achieve durable AR inhibition.
An additional occurrence in CRPC is the production of COOH-terminally truncated AR splice variants (AR-Vs). Diverse AR-Vs have been reported, all of which contain the AR NTD and DBD but lack the AR LBD (20) . Functional studies have demonstrated that AR-Vs can function as constitutively nuclear, constitutively active transcription factors (21) . AR-Vs are known to be enriched in CRPC and track with poor clinical outcomes (22) (23) (24) (25) . Recently, AR gene rearrangements were identified in CRPC cell lines that display high-level expression of AR-Vs (26, 27) . However, AR-Vs are coexpressed with fulllength AR in these cell lines, making pinpointing the precise contributions of AR-Vs to endocrine therapy resistance and a CRPC phenotype challenging. Here we report intragenic AR gene rearrangements in tissues from clinical CRPC metastases that completely block full-length AR synthesis. We modeled
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these intragenic rearrangements using transcription activatorlike effector nuclease (TALEN) genome engineering (28) , and found that these rearrangements underlie exclusive expression of truncated AR-Vs and uncoupling of the AR transcriptional program from endocrine regulation. Overall, this study characterizes a completely androgen-independent, AR-V-dependent resistance mechanism, and establishes the clinical relevance and a functional context of AR-Vs in CRPC. LuCaP 86.2 is a PCa xenograft established from a CRPC bladder metastasis resected from a 79-y-old patient (29) . This xenograft expresses full-length AR encoded by exons 1-8, and also expresses an AR-V protein thought to be an alternative splicing product arising from skipping of AR exons 5-7 (ARv567es) (30) . However, because AR is on the X chromosome, discovery of an 8.5-kb deletion of AR exons 5-7 in LuCaP 86.2 tissue indicates that ARv567es and full-length AR expression may be mutually exclusive and restricted to distinct cell populations (27) . In line with this idea, FISH and immunofluorescence staining demonstrated that all LuCaP 86.2 cells harbored a single AR gene copy and stained positive with an antibody specific for the AR NTD ( Fig. S1 A and  B) . However, high-resolution AR copy number analysis using a multiplex ligation-dependent probe amplification (MLPA) assay revealed deletion of the AR exon 5-7 segment encoding the AR LBD in approximately half of these cells (Fig. S1C) . The relative ratios of deletion-positive and deletion-negative cells remained stable during long-term propagation in castrated mice, as did expression ratios of full-length AR and ARv567es (Fig. S1 C and D) . Taken together, these findings demonstrate the existence of at least two stable CRPC subclones in heterogeneous LuCaP 86.2 tissue, one of which harbors an intragenic deletion of AR exons 5-7. To establish the clinical relevance of this finding, we used a PCR-based method and verified heterogeneity for cells with the 8.5-kb deletion breakpoint in both the LuCaP 86.2 xenograft and in CRPC cells procured by laser capture microdissection of archival patient tissue (Fig. 1A and Fig. S2 A-C) .
Interestingly, a different PCa xenograft established from CRPC abdominal ascites, LuCaP 136, also expresses ARv567es mRNA and protein (29, 30) . Whole-exome resequencing of LuCaP 136 genomic DNA (29) has not provided an obvious basis for ARv567es expression, and we did not detect intragenic deletion of AR exons 5-7 by PCR analysis (Fig. S2D) . Thus, we resequenced the 183-kb AR gene in LuCaP 136 genomic DNA via hybrid capture, followed by Illumina-based massively parallel paired-end sequencing. This analysis revealed a copy-neutral 8.7-kb inversion encompassing AR exons 5-7 ( (Fig. S3D) . No archival patient material corresponding to LuCaP 136 was available, and this intragenic AR inversion was discovered in tissue that had been propagated for only two passages in noncastrate male mice. Later passages of LuCaP 136 serially propagated in noncastrate male mice displayed coordinate loss of cells with this AR exon 5-7 inversion allele and AR v567es protein expression (Fig. S5) . Targeting Nucleases Recreate ARv567es-Associated Genome Rearrangements. To study the functional significance of these unique AR gene rearrangements in CRPC tissues, we pursued genome engineering in a monoclonal subline isolated from the CWR-R1 PCa cell line (31), termed R1-AD1 (32). R1-AD1 cells harbor one intact AR gene copy, express full-length AR, and exhibit growth stimulation in response to androgens and growth suppression in response to AR antagonists, including enzalutamide (32) . We constructed two TALEN pairs (28, 33, 34) , one pair targeting AR intron 4 (AR-int4) and the other pair targeting AR intron 7 (AR-int7) ( Fig. 2A and Fig. S6A ). Site-specific dsDNA cleavage by AR-int4 and AR-int7 TALENs was confirmed by assays measuring mutations introduced by TALEN cleavage and imprecise DNA repair (Fig. S6 B and  C) . When both AR-int4 and AR-int7 TALENs were coexpressed, deletion or inversion events involving the AR exon 5-7 segment were observed (Fig. S6 D-F) .
Using limiting dilution plating and PCR screening, we isolated and expanded two clonal cell lines derived from R1-AD1, one with a deletion (R1-D567) and the other with an inversion (R1-I567) of AR exons 5-7 (Fig. 2B) . AR exon copy number analysis by MLPA demonstrated that R1-AD1 and R1-I567 cells harbored one copy of each AR exon, whereas exons 5-7 had been deleted in R1-D567 cells (Fig. 2C) . Furthermore, the genome-engineered R1-I567 and R1-D567 cell lines displayed exclusive expression of ARv567es variant mRNA (Figs. 2 D and E and Fig. S7 ) and protein (Fig. 2F ). These findings confirm that the rearrangements involving the AR exon 5-7 segment discovered in CRPC tissues are causative events underlying the expression of ARv567es. (Fig. 3A) .
A possible explanation for the foregoing findings is that deletion or inversion of AR exons 5-7 functionally inactivates AR, causing an AR bypass mechanism in CRPC (35) . This would be consistent with the notion that full-length AR is required for AR-dependent CRPC progression, even when AR-Vs are expressed (36) . An alternative explanation could be that ARv567es, which retains the transcriptionally active AR NTD/DBD core (21) (Fig.  1C) , may be able to drive a completely ligand-independent, yet ARdependent, CRPC phenotype. To test this idea, we performed reporter assays with an AR-responsive mouse mammary tumor virus (MMTV) promoter. In parental R1-AD1 cells, MMTV displayed robust androgen induction, which was blocked by knockdown of full-length AR (Fig. 3B) . Conversely, in R1-D567 and R1-I567 cells, MMTV displayed constitutively high basal activity, but no androgen induction. However, high basal MMTV activity in R1-I567 and R1-D567 cells was blocked by knockdown of ARv567es (Fig. 3B ). These findings demonstrate that ARv567es is a constitutively active transcription factor in R1-I567 and R1-D567 cells.
We next tested whether constitutive ARv567es transcriptional activity could drive androgen-independent growth in R1-I567 and R1-D567 cells. DHT enhanced the growth of parental R1-AD1 cells, which was inhibited by knockdown of full-length AR (Fig. 3 C and D) . Conversely, R1-I567 and R1-D567 displayed robust androgen-independent growth, which was inhibited by knockdown of ARv567es (Fig. 3 C and D) . These data demonstrate that these AR gene rearrangements underlie a shift from a growth profile that is dependent on androgens and full-length AR to a growth profile driven by constitutive ARv567es activity.
ARv567es Effects a Constitutive Form of the Androgen/AR Transcriptional
Program. To determine whether ARv567es functions globally as a constitutive transcriptional regulator, we performed gene expression microarray analysis of parental R1-AD1 cells and R1-D567 cells. We first identified genes that were differentially expressed between full-length AR "on" (1 nM DHT) and "off" (vehicle control) states in R1-AD1 cells, then identified genes that were differentially expressed between ARv567es on (control siRNA) and off (siRNA targeting AR exon 1) states in R1-D567 cells. Overall, the majority of genes that displayed differential expression between ARv567es on and off states in R1-D567 also displayed a similar directional change between the AR on and off states in parental R1-AD1 cells (Fig. 4A ). This finding was confirmed for several shared target genes (FKBP5, FASN, and LIMA1) by direct qRT-PCR analysis (Fig.  S8 ). In line with this, knowledge-based Ingenuity Pathway Analysis (IPA) revealed that the only significant multigene networks displaying differential expression in parental R1-AD1 cells or R1-D567 cells had AR as the prominent central hub (Fig. S9) . Taken together, these findings indicate that ARv567es supports constitutive activation of a transcriptional program very similar to the program regulated by full-length AR.
We tested this idea more rigorously using gene set enrichment analysis (GSEA) (37) . Genes that were induced or repressed 1.2-fold by DHT in parental R1-AD1 cells were positively or negatively enriched, respectively, in the R1-D567 gene expression dataset (Fig. 4B) . Testing the reciprocal relationship yielded identical results; genes that were induced or repressed 1.2-fold by ARv567es in R1-D567 were positively or negatively enriched, respectively, in the R1-AD1 gene expression dataset (Fig. 4C and Dataset S1, Tables S4 and S5 ). Based on these findings, we conclude that AR gene rearrangements are a CRPC resistance mechanism through which the AR transcriptional program can be uncoupled from endocrine regulation.
Discussion
ARv567es and other AR-Vs are expressed in CRPC, but the mechanisms underlying this expression, and their functional significance, are poorly understood (20) . In previous studies, we showed that intragenic AR rearrangements occur in CRPC cell lines in which truncated AR-Vs were first discovered, explaining high-level AR-V expression concurrent with full-length AR in these models (26, 27) . For example, the 22Rv1 cell line harbors a 35-kb tandem duplication encompassing AR exon 3, and this intragenic duplication is associated with high-level mRNA and protein expression of the truncated AR-V7 (also referred to as AR3 and AR 1/2/3/CE3) and AR 1/2/3/2b (also referred to as AR-V4 and AR5) variants (21, 22, 24, 26, 38) . The CRPC CWR-R1 cell line harbors a population of cells with a 48-kb intragenic deletion of AR intron 1, and these deletion-positive cells display high-level AR-V7 expression and resistance to enzalutamide (22, 24, 27, 32) . These findings are associative, however, and have not established a clear cause-and-effect relationship between AR gene rearrangements and functional AR-V expression. The data presented here demonstrate that CRPC LuCaP 86.2 and LuCaP 136 tissues also harbor intragenic rearrangements, associated with expression of the ARv567es variant. This study provides an important breakthrough, establishing a causal relationship between specific genome rearrangements discovered in CPRC tissues and functionally significant AR-V expression. By modeling these specific intragenic AR gene rearrangements using a unique TALEN genome engineering approach, we have demonstrated that these genomic events underlie a true androgen-independent phenotype On day 20, plates were tested for enrichment of cells with AR deletion or inversion alleles relative to all AR alleles (intron 2) by qPCR (n = 6). P values were calculated using the two-tailed t test. Error bars represent SD. (B) Promoter-reporter assays following cotransfection with an AR-responsive MMTV-luciferase reporter and siRNAs targeted to AR exon 7 or AR exon 1. Transfected cells were treated for 24 h with 1 nM DHT as indicated. Results are presented as means (n = 3). P values were calculated using the two-tailed t test. Data are shown for one triplicate experiment representative of three independent biological replicates, each of which reached statistical significance (P < 0.05). Error bars represent SD. (C) Western blots for the AR NTD or ERK-2 (loading control) in R1-D567 and parental R1-AD1 cells transfected with siRNAs targeting AR exon 1. (D) Growth assays of parental R1-AD1 cells and genome-engineered R1-I567 and R1-D567 cells transfected as in C (n = 4). P values shown are the largest of any comparison between bracketed groups and were calculated using the two-tailed t test. Data are shown for one quadruplicate experiment representative of two independent biological replicates, each of which reached statistical significance (P < 0.05). Error bars represent SD.
through a mechanism of switching AR expression from full-length AR to ARv567es. Furthermore, we have established ARv567es as the active protein driving this androgen-independent phenotype by effecting a broad androgen/AR transcriptional program.
A rearrangement-dependent mechanism of AR-V expression in CRPC tissues contrasts with the previous report of acute increases in AR-V7 expression in VCaP and late-passage LNCaP cells in response to endocrine targeting therapy (39) , supporting growth of VCaP cells when full-length AR is inhibited (40) . This plasticity in AR-V expression might be attributable to a negative feedback loop in which transcription of the AR gene is actively repressed by androgen-bound full-length AR via recruitment of lysine-specific demethylase 1 (41) . Based on this mechanism, AR inhibition would lead to transcriptional derepression and increased expression of both full-length AR and AR-V7. However, unlike AR gene rearrangements, this mechanism does not appear to affect relative expression ratios, and AR-V7 remains a minor constituent of overall AR expression (39, 40) .
Tumor heterogeneity and subclonal architecture are not apparent when lysates from cell lines or tissues are assessed for mRNA or protein expression. A frequent finding in CRPC cell lines and tissues, including LuCaP 86.2 and LuCaP 136, is the concurrent expression of AR-Vs and full-length AR (22) (23) (24) (25) 30) . Modeling this coexpression by transfecting AR-Vs in LNCaP cells led to the conclusions that full-length AR and ARv567es can physically interact (30) , that ARv567es facilitates nuclear localization and transcriptional activation of full-length AR under castrate conditions (30) , that full-length AR is required for ARv567es to drive features of the CRPC phenotype (30, 36) , and that antiandrogens such as enzalutamide can inhibit full-length AR and thereby inhibit any effects of AR-Vs (36) . Our findings underscore the importance of understanding the subclonal architecture of CRPC cell lines and tumor tissue when assessing AR-V expression and function. Indeed, there have been conflicting reports about the association of AR-V expression levels with clinical disease progression (22) (23) (24) (25) 42) , and our findings suggest that this could be related to the variable degree to which heterogeneous CRPC tumors are enriched for AR-V-expressing cells.
The majority of men who progress on abiraterone and enzalutamide display rising serum levels of the AR-regulated prostatespecific antigen gene, indicating that these tumors remain ARdriven (13, 15, 43) . This finding has spurred ongoing development of additional endocrine therapies that act on the AR LBD (18, 44, 45) . Importantly, the AR gene rearrangements discovered and modeled in the present study provide a complete genetic block of full-length AR and represent a previously unanticipated endocrine uncoupling escape mechanism. Identification of AR-Vs as the ultimate functional outcome of this mechanism demonstrates the need for development of new therapies targeted to the AR-V core, which is composed of the transcriptionally active AR NTD and AR DBD (46, 47) . In addition, this work highlights an opportunity to develop AR gene rearrangements as stable biomarkers of resistance to endocrine-targeting therapies for PCa.
Materials and Methods
Tissues. Genomic DNA samples from the LuCaP series of PCa xenografts and deidentified clinical CRPCa tissue were obtained from the University of Washington's Prostate Cancer Biorepository, which was developed and managed by one of the coauthors (R.L.V.) and has been described previously (25, 29, 30) .
Cell Lines. The LNCaP (CRL-1740) cell line was obtained from American Type Culture Collection, and CWR-R1 cells were provided by Dr. Elizabeth Wilson, University of North Carolina, Chapel Hill, NC. The R1-AD1 cell line (CWR-R1, androgen-dependent 1, referred to as "deletion-negative clone 1" in the original publication) (27) is a subline derived from single-cell cloning of the CWR-R1 cell line. R1-AD1 cells are androgen-responsive and contain a structurally normal copy of the AR gene (27, 32) . Cells were maintained in in RPMI 1640 medium supplemented with 10% (vol/vol) FBS in a 5% CO 2 incubator at 37°C.
MMTV-Luciferase Reporter Assays. Promoter-reporter assays with an MMTVluciferase reporter were performed as described previously (38) .
Cell Growth Assays. Cell growth was monitored by crystal violet staining as described previously (26) . Western Blot Analysis. Western blot analysis was performed as described previously (26) using antibodies specific for the AR NTD (N-20; Santa Cruz Biotechnology) and ERK2 (D-2, Santa Cruz Biotechnology).
Generation of R1-D567 and R1-I567 Cell Lines. For isolation of clonal cell lines with targeted intragenic deletion or inversion of the AR exon 5-7 segment, cells were electroporated with TALENs, plated, and allowed to recover for 3 d. Transfected cells were transferred to tissue culture dishes at limiting dilution. When colonies became visible (∼3 wk to 1 mo), cells were picked, trypsinized, and plated on 96-well plates. Clones were expanded and split into two separate plates, one of which was used for PCR screening. Genomic DNA was extracted using the QuickExtract Kit (catalog no. QE0905T; Epicentre-Illumina) according to the manufacturer's protocol. Genomic DNA was then used for PCR screening with rearrangement-specific primers (Dataset S1). Positive clones were expanded. The clonal purity of R1-D567 and R1-I567 cell lines was assessed by secondary PCR screening, and met the criteria of positive PCR signals with rearrangement-specific primers and negative PCR signals with WT-specific primers (Dataset S1).
MLPA. MLPA assays were performed as described previously (27) .
Gene Expression Microarray Analysis. Gene expression microarray analysis using Illumina Human HT-12 V4 BeadChips was performed as described previously (32) . Triplicate biological samples were used for analysis. R1-D567 cells were electroporated with either control siRNA (siCNTL) or siAR-exon1 (Dataset S1). R1-AD1 cells were electroporated with siCNTL. Electroporated cells were plated in RPMI 1640 medium supplemented with 10% CSS. After 48 h, cells were switched to serum-free RPMI 1640 medium supplemented with 1 nM DHT or 0.1% (vol/vol) ethanol (vehicle control) for 24 h. Gene lists were derived from genes displaying an ≥1.2-fold expression increase or decrease (P = ≤ 0.05 with Benjamini-Hochberg false discovery rate correction) in R1-AD1 1 nM DHT vs. EtOH and in R1-D567 siCNTL vs. siAR-exon1. Heat maps were generated using Cluster 3.0 software (http://bonsai.hgc.jp/ ∼mdehoon/software/cluster/software.htm). Data are available at the National Center for Biotechnology Information's Gene Expression Omnibus (accession no. GSE49196).
GSEA. Differentially expressed genes were analyzed for enrichment in normalized gene expression datasets using GSEA analysis software v2.0.10 (http://www.broadinstitute.org/gsea/index.jsp). Normalized gene expression data were ranked using the Signal2Noise metric, and GSEA was performed against 1,000 random gene set permutations. All other analysis options were kept at the default setting.
Additional Materials and Methods. Detailed information on FISH, immunofluorescence staining, next-generation paired-end AR gene resequencing, transient transfections, RT-PCR, genomic PCR, cloning of PCR products, TALEN nuclease construction, Surveyor nuclease assays, and microarray sample preparation and analysis is available in SI Materials and Methods.
